Cargando…
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125897/ https://www.ncbi.nlm.nih.gov/pubmed/18407505 http://dx.doi.org/10.1016/j.bmc.2008.03.059 |
_version_ | 1783516043011948544 |
---|---|
author | Huitema, Carly Zhang, Jianmin Yin, Jiang James, Michael N.G. Vederas, John C. Eltis, Lindsay D. |
author_facet | Huitema, Carly Zhang, Jianmin Yin, Jiang James, Michael N.G. Vederas, John C. Eltis, Lindsay D. |
author_sort | Huitema, Carly |
collection | PubMed |
description | The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study of the severe acute respiratory syndrome (SARS) 3CL proteinase against Hepatitis A virus (HAV) 3C(pro). Three of the compounds, which also had furan rings, inhibited the cleavage activity of HAV 3C(pro) with K(ic)s of 120–240 nM. HPLC-based assays revealed that the inhibitors were slowly hydrolyzed by both HAV 3C(pro) and SARS 3CL(pro), confirming the identity of the expected products. Mass spectrometric analyses indicated that this hydrolysis proceeded via an acyl-enzyme intermediate. Modeling studies indicated that the halopyridinyl moiety of the inhibitor fits tightly into the S1-binding pocket, consistent with the lack of tolerance of the inhibitors to modification in this portion of the molecule. These compounds are among the most potent non-peptidic inhibitors reported to date against a 3C(pro). |
format | Online Article Text |
id | pubmed-7125897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71258972020-04-08 Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action Huitema, Carly Zhang, Jianmin Yin, Jiang James, Michael N.G. Vederas, John C. Eltis, Lindsay D. Bioorg Med Chem Article The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study of the severe acute respiratory syndrome (SARS) 3CL proteinase against Hepatitis A virus (HAV) 3C(pro). Three of the compounds, which also had furan rings, inhibited the cleavage activity of HAV 3C(pro) with K(ic)s of 120–240 nM. HPLC-based assays revealed that the inhibitors were slowly hydrolyzed by both HAV 3C(pro) and SARS 3CL(pro), confirming the identity of the expected products. Mass spectrometric analyses indicated that this hydrolysis proceeded via an acyl-enzyme intermediate. Modeling studies indicated that the halopyridinyl moiety of the inhibitor fits tightly into the S1-binding pocket, consistent with the lack of tolerance of the inhibitors to modification in this portion of the molecule. These compounds are among the most potent non-peptidic inhibitors reported to date against a 3C(pro). Elsevier Ltd. 2008-05-15 2008-03-27 /pmc/articles/PMC7125897/ /pubmed/18407505 http://dx.doi.org/10.1016/j.bmc.2008.03.059 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Huitema, Carly Zhang, Jianmin Yin, Jiang James, Michael N.G. Vederas, John C. Eltis, Lindsay D. Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title_full | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title_fullStr | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title_full_unstemmed | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title_short | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action |
title_sort | heteroaromatic ester inhibitors of hepatitis a virus 3c proteinase: evaluation of mode of action |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125897/ https://www.ncbi.nlm.nih.gov/pubmed/18407505 http://dx.doi.org/10.1016/j.bmc.2008.03.059 |
work_keys_str_mv | AT huitemacarly heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction AT zhangjianmin heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction AT yinjiang heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction AT jamesmichaelng heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction AT vederasjohnc heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction AT eltislindsayd heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction |